Literature DB >> 19571330

The half-cycle correction: banish rather than explain it.

Jan J Barendregt1.   

Abstract

The half-cycle correction is often used in discrete Markov models to estimate state membership. This article shows that the correction, in addition to being unintuitive, actually produces the wrong results in many circumstances. These include quality-adjusted life year (QALY) weights and unit costs that differ by cycle. The half-cycle correction is also incompatible with discounting of the obtained stream of state membership. It is furthermore shown that the life table method of estimating state membership obtains correct results under these circumstances and is also much more transparent. The article concludes that the half-cycle correction should be dropped in favor of the life table method.

Mesh:

Year:  2009        PMID: 19571330     DOI: 10.1177/0272989X09340585

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  16 in total

1.  Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers.

Authors:  Elamin H Elbasha; Jagpreet Chhatwal
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

2.  Continuous time simulation and discretized models for cost-effectiveness analysis.

Authors:  Marta O Soares; Luísa Canto E Castro
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

3.  Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada.

Authors:  William Herring; Isobel Pearson; Molly Purser; Hamid Reza Nakhaipour; Amin Haiderali; Sorrel Wolowacz; Kavisha Jayasundara
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

4.  Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation.

Authors:  Elizabeth Hancock; Zoe Ward; Rachel Ayres; Jane Neale; Deborah Hussey; Joanna May Kesten; Matthew Hickman; Peter Vickerman
Journal:  Addiction       Date:  2019-11-19       Impact factor: 6.526

5.  Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany.

Authors:  Afschin Gandjour; Dennis A Ostwald
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

6.  Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.

Authors:  Nihar R Desai; Caresse Campbell; Batul Electricwala; Margaret Petrou; David Trueman; Fionn Woodcock; Joaquim Cristino
Journal:  Am J Cardiovasc Drugs       Date:  2022-05-21       Impact factor: 3.283

7.  A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.

Authors:  Björn Stollenwerk; Sergio Iannazzo; Ron Akehurst; Michael Adena; Andrew Briggs; Bastian Dehmel; Patrick Parfrey; Vasily Belozeroff
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

8.  Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.

Authors:  M Ruggeri; M Basile; C Drago; F R Rolli; A Cicchetti
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

9.  Comparison of Decision Modeling Approaches for Health Technology and Policy Evaluation.

Authors:  John Graves; Shawn Garbett; Zilu Zhou; Jonathan S Schildcrout; Josh Peterson
Journal:  Med Decis Making       Date:  2021-03-18       Impact factor: 2.749

10.  Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study.

Authors:  Renee Lévesque; Daniele Marcelli; Héloïse Cardinal; Marie-Line Caron; Muriel P C Grooteman; Michiel L Bots; Peter J Blankestijn; Menso J Nubé; Aileen Grassmann; Bernard Canaud; Afschin Gandjour
Journal:  Appl Health Econ Health Policy       Date:  2015-12       Impact factor: 2.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.